Evidence map›Paper›PMID 33570248›Full record

Trial reportPharmacology research & perspectives2021

Achieving optimal adherence to medical therapy by telehealth: Findings from the ORBITA medication adherence sub-study.

David Thompson, Rasha Al-Lamee, Michael Foley, Hakim M Dehbi, Simon Thom, Justin E Davies, Darrel P Francis, Prashanth Patel, Pankaj Gupta, ORBITA Investigators

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pharmacology research & perspectives, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

David ThompsonNational Heart and Lung Institute, Imperial College London, London, UK.ORCID 0000-0002-0850-7784
Rasha Al-LameeNational Heart and Lung Institute, Imperial College London, London, UK.
Michael FoleyNational Heart and Lung Institute, Imperial College London, London, UK.
Hakim M DehbiComprehensive Clinical Trials Unit at UCL, University College London, London, UK.
Simon ThomNational Heart and Lung Institute, Imperial College London, London, UK.
Justin E DaviesNational Heart and Lung Institute, Imperial College London, London, UK.
Darrel P FrancisNational Heart and Lung Institute, Imperial College London, London, UK.
Prashanth PatelDepartment of Chemical Pathology and Metabolic Diseases, University Hospitals of Leicester, Leicester, UK.
Pankaj GuptaDepartment of Chemical Pathology and Metabolic Diseases, University Hospitals of Leicester, Leicester, UK.
ORBITA Investigators
Imperial College London · GBUniversity College London · GBUniversity of Leicester · GBAssociated Press · US

Funding

British Heart Foundation FS/17/16/32560Department of HealthMedical Research Council MR/V001620/1
6 · The paper itself

Abstract

introductionThe ORBITA trial of percutaneous coronary intervention (PCI) versus a placebo procedure for patients with stable angina was conducted across six sites in the United Kingdom via home monitoring and telephone consultations. Patients underwent detailed assessment of medication adherence which allowed us to measure the efficacy of the implementation of the optimization protocol and interpretation of the main trial endpoints.

methodsPrescribing data were collected throughout the trial. Self-reported adherence was assessed, and urine samples collected at pre-randomization and at follow-up for direct assessment of adherence using high-performance liquid chromatography with tandem mass spectrometry (HPLC MS/MS).

resultsSelf-reported adherence was >96% for all drugs in both treatment groups at both stages. The percentage of samples in which drug was detected at pre-randomization and at follow-up in the PCI versus placebo groups respectively was: clopidogrel, 96% versus 90% and 98% versus 94%; atorvastatin, 95% versus 92% and 92% versus 91%; perindopril, 95% versus 97% and 85% versus 100%; bisoprolol, 98% versus 99% and 96% versus 97%; amlodipine, 99% versus 99% and 94% versus 96%; nicorandil, 98% versus 96% and 94% versus 92%; ivabradine, 100% versus 100% and 100% versus 100%; and ranolazine, 100% versus 100% and 100% versus 100%.

conclusionsAdherence levels were high throughout the study when quantified by self-reporting methods and similarly high proportions of drug were detected by urinary assay. The results indicate successful implementation of the optimization protocol delivered by telephone, an approach that could serve as a model for treatment of chronic conditions, particularly as consultations are increasingly conducted online.

Indexed as

Drug MonitoringPercutaneous Coronary InterventionTelemedicineAgedAngina, StableCalcium Channel BlockersCardiovascular AgentsFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPlatelet Aggregation InhibitorsSelf ReportSingle-Blind MethodUnited KingdomCalcium Channel BlockersCardiovascular AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsPlatelet Aggregation Inhibitorscardiovascular diseaseschromatography, liquidcoronary artery diseasemedication adherencetherapeutics

Identifiers

PMID33570248
PMCPMC7876856
OpenAlexW3128353151

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.